M&G plc’s Arcutis Biotherapeutics ARQT Stock Holding History

M&G plc’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-469,082	Closed	-$11.3M	–	378
2026 Q1	$11.3M	Buy	+469,082	New	+$12M	0.06%	195

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

M&G plc's ARQT Position: Q2 2026 in Review

M&G plc sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 469,082 shares — an estimated $11.3M sold.

M&G plc first reported a position in ARQT in Q1 2026 and held it in 1 quarter. The position peaked at $11.3M in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

M&G plc reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
M&G plc sold 469,082 Arcutis Biotherapeutics shares in Q2 2026, an estimated $11.3M.
M&G plc first reported a position in Arcutis Biotherapeutics in Q1 2026 and held it in 1 quarter.
M&G plc's Arcutis Biotherapeutics position peaked at $11.3M in Q1 2026.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on M&G plc's 13F filing for Q2 2026, filed 6 Aug 2026.